BioSpace News Archive

Albumin is a water soluble globular protein produced in the liver. It accounts for 50% of blood plasma proteins.

Quotient Limited, headquartered in Eysins, Switzerland, announced that on September 25, 2020, the U.S. Food and Drug Administration issued an Emergency Use Authorization for Quotient’s COVID-19 antibody test.

Quench Bio, a company driving new insights into gasdermin biology and innate immunology to develop medicines for severe inflammatory diseases, announced that it has been named by Fierce Biotech as one of 2020’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

Illumina, Inc. announced that it will issue results for the third quarter 2020 following the close of market on Thursday, October 29, 2020.

Economic and competitive pressures in the healthcare industry continue to motivate life sciences companies to explore ways of cutting costs across operations and increase their focus on product innovations, research activities, and improved turnaround time of deliverables.

- First Healthy Adult Volunteers Safely Dosed with UB-612 - Clinical Trial Currently Enrolling up to 60 Healthy Volunteers - Taiwan’s Ministry of Health and Welfare Approves Up to $15M (USD) Grant to Support Phase 1 and 2 of Human Trials - Clinical Trial Expands on Existing International Collaborations with Brazil and U.S.

New findings to be presented at The North American Menopause Society (NAMS) 2020 Virtual Annual Meeting

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces it has dosed two patients in a phase 1 clinical trial of its dual cytokine armed oncolytic adenovirus, TILT-123, in Denmark’s Herlev hospital in Copenhagen.

Full Class II De Novo FDA Submission seeking clearance of the Parsortix system for metastatic breast cancer

AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, will hold a live business update focused on the company’s Alzheimer’s platform Alzstatin on Wednesday, September 30 at 10:00.